POXEL SA (POXEL.PA) Stock Price, Quote, News and Overview
EPA:POXEL - Euronext Paris - Matif - FR0012432516 - Common Stock - Currency: EUR
POXEL.PA Quote, Performance and Key Statistics
POXEL SA
EPA:POXEL (1/23/2025, 4:20:06 PM)
0.336
+0.03 (+8.39%)
The current stock price of POXEL.PA is 0.336 EUR. In the past month the price increased by 142.95%. In the past year, price decreased by -34.94%.
POXEL.PA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 15.83 | 287.83B | ||
| AMG.DE | AMGEN INC | 14.3 | 141.45B | ||
| GIS.DE | GILEAD SCIENCES INC | 20.87 | 110.28B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 839.59 | 105.95B | ||
| ARGX.BR | ARGENX SE | N/A | 36.97B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 26.51B | ||
| IDP.DE | BIOGEN INC | 8.75 | 19.93B | ||
| 0QF.DE | MODERNA INC | N/A | 14.37B | ||
| 1MRNA.MI | MODERNA INC | N/A | 14.29B | ||
| ALEMS.BR | EUROPEAN MEDICAL SOLUTIONS S | N/A | 9.53B | ||
| BIO.DE | BIOTEST AG | 24.33 | 1.65B | ||
| GLPG.AS | GALAPAGOS NV | 7.3 | 1.51B |
Related screens
About POXEL.PA
Company Profile
Poxel SA operates as a clinical-stage biopharmaceutical company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 22 full-time employees. The company went IPO on 2015-02-06. The firm develops drugs with a focus on Type 2 diabetes. The firm aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The firm cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.
Company Info
POXEL SA
Imm Le Sunway, 259/261 Avenue Jean Jaures
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 22
Company Website: https://www.poxelpharma.com/
Investor Relations: http://www.poxelpharma.com/en_us/investors
Phone: 33437372010
POXEL.PA FAQ
What is the price of POXEL.PA?
The current price of POXEL.PA is 0.336 EUR.
What is the symbol for POXEL SA?
The exchange symbol of POXEL SA is POXEL and it is listed on the Euronext Paris - Matif exchange.
On which exchange is POXEL.PA listed?
POXEL.PA is listed on the Euronext Paris - Matif exchange.
Is POXEL.PA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for POXEL.PA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of POXEL.PA.
Does POXEL.PA pay dividends?
POXEL.PA does not pay a dividend.
When does POXEL.PA report earnings?
POXEL.PA will report earnings on 2025-02-12, after the market close.
What is the Price/Earnings (PE) ratio of POXEL.PA?
POXEL.PA does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.08).
POXEL.PA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to POXEL.PA. When comparing the yearly performance of all stocks, POXEL.PA is a bad performer in the overall market: 92.44% of all stocks are doing better.
POXEL.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to POXEL.PA. Both the profitability and financial health of POXEL.PA have multiple concerns.
POXEL.PA Financial Highlights
Over the last trailing twelve months POXEL.PA reported a non-GAAP Earnings per Share(EPS) of -1.08. The EPS increased by 0.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -727.56% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
POXEL.PA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to POXEL.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -58.3% and a revenue growth 3450% for POXEL.PA